A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

• Published in: Clinical ophthalmology (Auckland, N.Z.) Vol. 13; pp. 215 - 216
• Main Authors: Tauber, Joseph, Schechter, Barry A, Bacharach, Jason, Toyos, Melissa M, Smyth-Medina, Robert, Weiss, Sidney L, Luchs, Jodi I
• Format: Journal Article
• Language: English
• Published: Auckland Taylor & Francis Ltd 01-01-2019; Dove Medical Press
• Subjects: Corrigendum
• ISSN: 1177-5483; 1177-5467; 1177-5483
• DOI: 10.2147/OPTH.S201658

Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol.2018;12:1921-1929.On page 1927, "Safety and tolerability assessments" section,third paragraph, first sentence should read from "Fifteensubjects exited the study due to AEs: 5 subjects (3.3%) in theOTX-101 0.09% group, 4 subjects (2.6%) in the OTX-1010.09% group, and 6 subjects (3.9%) in the vehicle group."to "Fifteen subjects exited the study due to AEs: 5 subjects(3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) inthe OTX-101 0.05% group, and 6 subjects (3.9%) in thevehicle group."Read the original articlePrevious corrigendum has been published